The aim of this study was to evaluate the effects of anti-inflammatory intake on cognitive function in 7234 community-dwelling elderly persons. Cognitive performance, clinical diagnosis of dementia, and anti-inflammatory use were evaluated at baseline, and 2, 4, and 7 years later.
Introduction
In the absence of effective treatment for neuro-degenerative disorders, research has focused on the identification of modifiable risk factors to delay cognitive decline and prolong autonomy . There is some evidence that corticosteroids (CS) could be associated with reversible cognitive dysfunction.; both experimental and epidemiological research showing that dysregulation of the hypothalamic-pituitary-adrenal (HPA) corticotropic axis, a major component of the stress response system, may lead to, or accelerate hippocampal impairment (Belanoff et al., 2001; Conrad and Bimonte-Nelson, 2010; Lupien et al., 2007) . This may be especially important in the ageing brain, more vulnerable to stress effects and subject to decrements in cognitive performance due to multiple causes.
Several studies in the elderly have demonstrated a potentially reversible link between elevated endogenous cortisol levels and decline in memory and frontal-executive abilities (Greendale et al., 2000; O'Hara et al., 2007; Seeman et al., 1997; Li et al., 2006; Beluche et al., 2010; Egeland et al., 2005) and dementia (Umegaki et al., 2000; Rasmuson et al., 2002; Csernansky et al., 2006) . Associations between short-term CS administration and cognitive impairment have been reported in small experimental and clinical studies in adults (Wolkowitz et al., 2009; Newcomer et al., 1999; Kirschbaum et al., 1996; Lupien et al., 2007; Young et al., 1999; de Quervain et al., 2003; Keenan et al., 1996) . The effect of chronic CS administration has, however, never been examined in elderly populations who have high rates of both prescribed and over the counter drug use (Hilmer et al., 2007) .
Previous studies have failed to take into account the potential confounding effects on cognitive decline of pathologies associated with CS use, e.g. chronic pain and respiratory disorders, or the impact of CS administration mode, oral administration being generally associated with slower absorption and lower biologically active circulating metabolites than inhaled CS. Surprisingly, genetic vulnerability has also not been considered despite a possible interactive effect between cortisol levels and apolipoproteinE allele (APOE (Lee et al., inserm-00782581, version 1 -30 Jan 2013 . Finally, gender differences have not been examined although they have been reported in relation to both stress response and association between cortisol levels and cognitive decline and neural activity (Otte et al., 2005; Sauro et al., 2003; Seeman et al., 1997; Wang et al., 2007; Beluche et al., 2010) as well as in risk profiles for cognitive impairment and progression to dementia (Artero et al., 2008) .
Thus, while there is accumulating evidence to suggest that CS treatment may increase risk of cognitive decline and dementia in the elderly, this hypothesis remains to be tested within a large study able to take into account multiple competing causes of cognitive decline. This prospective study aims to examine the relationship between CS use and cognitive decline and dementia onset in community-dwelling elderly taking into account gender, genetic vulnerability, and reasons for CS use. The cognitive effects of other nonsteroidal anti-inflammatory drugs (NSAID) were also examined.
Methods

Study population
Subjects were recruited as part of a multi-site cohort study of community-dwelling persons aged 65 years and over from the electoral rolls of three French cities between 1999 and 2001 (The 3C Study Group, 2003) . The study protocol was approved by the Ethical Committee of the University-Hospital of Bicêtre (France). Written informed consent was obtained from each participant. Participants were administered standardized questionnaires by trained staff and underwent clinical examinations at baseline and at each 2, 4, and 7year follow-up. Of the 9080 dementia-free participants included, 629 died having only one cognitive evaluation at baseline, 704 were alive at the end of the follow-up but did not have repeated cognitive testing, and 513 had missing data for at least one adjustment variable. The present analyses were conducted on 7234 subjects. The mean (SD) age was 73.6 (5.3) for men and 73.8 (5.2) for women. The average follow-up (median, IQR) was 6.7 (3.8-7.2) years. Subjects not included in the analysis inserm-00782581, version 1 -30 Jan 2013
were significantly older, with lower education levels, and worse physical and mental health, lower baseline cognitive scores, and were more frequently CS users.
Cognitive measures and dementia
The Isaacs Set Test (Isaacs and Kennie, 1973) provided a measure of verbal fluency or semantic access. The Benton Visual Retention Test (Benton, 1965) assessed visual memory and the Trail Making Tests (TMT) A and B psychomotor speed and executive function respectively (Reitan, 1965) . The Mini Mental State Examination (MMSE) was used as a global measure of cognitive function (Folstein et al., 1975) . All tests were administered at baseline, and waves 1, 2, and 3 of the follow-up, except the TMT which was not given in wave1. Consequently, analyses relating to these tasks involved only 6085 participants.
A preliminary diagnosis and classification of dementia at each follow-up examination was made by the study clinical investigators according to DSM-IV revised criteria (American Psychiatric Association, 1994) and independently validated by a national panel of neurologists (The 3C Study Group, 2003) . The onset of dementia was the date of the follow-up interview when dementia was diagnosed.
Corticosteroid and NSAID use
All prescription and over-the-counter drugs used more than once a week over the preceding month were recorded in a standardized interview. Medical prescriptions and the medications themselves were checked by the interviewer. Oral and inhaled but not topical applications were considered in this analysis.
Socio-demographic and clinical variables
The standardized interview included questions on socio-demographic and lifestyle characteristics with evaluation of hypertension, hypercholesterolemia, and diabetes. Fasting inserm-00782581, version 1 -30 Jan 2013 blood samples were taken at baseline for lipid and glucose levels and APOE4 genotyping (Ritchie et al., 2007) . History of ischemic pathologies (stroke, angina pectoris, myocardial infarction and cardio-vascular surgery) was established according to standardized questions.
Chronic bronchitis (daily sputum or mucus production or cough for at least 3 consecutive months/year), other chronic respiratory disorders including wheezing, tachypnea, and asthma attacks (over the last 12months) were self-reported as well as chronic/regular joint or back pain.
Depressive symptomatology was assessed by the Center for Epidemiological Studies-Depression Scale (CES-D) (Radloff, 1977 ) with a 16 cut-off point.
Statistical analyses
We used logistic regression analyses to determine whether baseline anti-inflammatory use was associated with odds of cognitive decline. Men and women were examined in separate analyses as they differed in both anti-inflammatory drug use and profiles of cognitive ability.
The Chi2 test was used to identify gender-related differences. After gender stratification, OR were adjusted for centre, age, educational level, and baseline cognitive performance (minimally adjusted model). Multivariate adjusted logistic regression further included covariates associated with cognitive decline (at p<0.15); depression, diabetes, hypercholesterolemia, caffeine, smoking, APOE4, ischemic pathologies, chronic joint or back pain, bronchitis, asthma and other chronic respiratory disorders. Due to the skewed distribution of cognitive scores, a substantial decline in cognitive function over follow-up was defined as the lowest quintile of the difference between either follow-up visit and baseline score except for response time recorded for the TMT, for which the highest quintile of the difference was considered (Ritchie et al., 2007) . We also used random-effect models to analyze the association between CS use and 7-year change on cognitive scores taken as continuous variables. In order to normalize the distribution, represents the cross-sectional association between CS and baseline cognitive score. The term time indicates the linear evolution per year on the cognitive test. The term for interaction represents the additional annual modification on the selected cognitive tests for CS use. A Cox model with delayed entry was used in the analysis of dementia incidence taking age as the basic time scale and birth as the time origin (Commenges et al., 1998) . This analysis was undertaken on 7486 subjects without missing data for baseline adjustment variables but with possibly missing repeated cognitive testing. Analyses were carried out using SAS software (version 9.1).
Results
Subject characteristics
Within this elderly community-dwelling sample, 352 of the 7234 subjects (4.9%) were taking CS at baseline, of whom 112 (1.6%) used oral and 240 (3.3%) inhaled preparations. Oral CS principally consisted of prednisone (16.2% of CS users), prednisolone (4.9%), methylprednisolone (2.8%) and hydrocortisone (2.3%). The main inhaled CS were beclometasone (27.4%), budesonide (20.5%), fluticasone (12.1%) and triamcinolone (5.9%)
(table e-1). Fifteen subjects were taking simultaneously inhaled and oral CS. Both oral and inhaled prednisolone and triamcinolone were used, the former being predominantly by oral administration and the latter inhaled. Women used more frequently oral (1.7%) and less frequently inhaled (3.0%) CS than men (1.3% and 3.9%, respectively, p=0.04). Men and women were found to significantly differ on all other characteristics at baseline except APO4. A higher proportion of women showed low scores on the MMSE, Benton, and TMTA and TMTB but not on the Isaacs test (data not shown).
For both men and women, CS use was higher in subjects with chronic joint or back pain and respiratory disorders (p<0.0001) ( Table 1 ). Men with lower education level and low MMSE
and Isaacs scores at baseline were more frequent CS users (p<0.05), whereas women using CS tended to have lower performance on TMTB (p=0.06).
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CS use and cognitive decline
Logistic regression analysis adjusted for age, center, education level and baseline cognitive performance indicated that women reporting use of inhaled but not oral CS at baseline showed greater decline over 7years on the TMTB (OR=1.65, 95%CI=1.10-2.47) ( Table 2 ). The association persisted in the complete model further adjusted for other confounders including pathologies associated with CS prescription (chronic pain and respiratory disorders, etc.) (OR=1.76, 95%CI=1.14-2.71). No significant interactions were found for decline on TMTB in women between CS use and age (p=0.12) or APOE (p=0.38). No significant effect was observed in men regardless of the cognitive domain. Performing multivariate-adjusted random-effect linear models with the cognition score as the continuous variable led to the same results, the only significant association being found between CS use and performance on the TMTB in women (interaction between time and inhaled CS p=0.003, slope of log(TMTB) increased by 0.008 compared to no CS use). Similar findings were observed when executive function was assessed using score differences such as time on TMTB minus time on TMTA (data not shown).
Cognitive decline according to the pattern of CS use during follow-up
Of the 3736 women with a TMT evaluation, 3171 (84.9%) did not report CS use (oral or inhaled) at baseline and during the 7-year follow-up, 38 (1.0%) reported inhaled CS use only at baseline or after the first 2-year follow-up, but not at either 4-or 7-year follow-up ("discontinuing" group), and 22 (0.5%) reported inhaled CS use both at baseline and at least at the 2-and 4-year examination (3 consecutive examinations, "continuing" group). Other subjects having reported inhaled CS use intermittently during the follow-up or having taken oral CS at baseline or during the follow-up (n=505) were not considered in the following analyses.
Compared to women who had never used CS, women having continuously used inhaled CS were at higher risk of cognitive decline on the TMTB in fully-adjusted models (OR=3.15,
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95%CI=1.29-7.68, p=0.01) ( Table 3 ). The association was not significant for women in the "discontinuous" group (OR=1.41, 95%CI=0.69-2.89, p=0.35).
NSAID and cognitive decline
A total of 180 men (6.4%) and 452 women (10.3%) were taking NSAID at baseline.
Thirty-four (0.5%) were taking both NSAID and CS. NSAID principally consisted of diacerein (23.1% of users), diclofenac (14.5%), piroxicam (14.2%), ketoprofen (9.9%), and ibuprofen (8.6%) and 6.8% were taking coxibs (table e-2). There was no significant association between NSAID use at baseline and cognitive decline in men and women ( 
Dementia incidence
Within the 7486 subjects included in the analysis 527 incident cases were diagnosed during the 7-year follow-up, of whom 360 had Alzheimer's disease (AD). Adjusted Cox models failed to find a significant association between the incidence of dementia or AD and CS or NSAID use at baseline ( Table 5) .
Discussion
CS use and cognitive decline
Our results indicate a 1.8-fold increased risk of decline in a cognitive task sensitive to alterations in psychomotor speed and frontal executive functioning in women only. The same results were obtained in the minimally and the fully adjusted model, which was further adjusted for the pathologies associated with CS treatment (such as chronic pain and respiratory disorders) (Belanoff et al., 2001 ) and using two different models (logistic regression and random-effect inserm-00782581, version 1 -30 Jan 2013 models). This underlines the consistency of these associations, in spite of an eventual risk of over-adjustment and suggests that the cognitive decline was more likely related to the CS themselves rather than the underlying burden of illness, making unlikely an eventual prescription bias. This is also supported by the observation that risk of cognitive decline nearly doubled (OR=3.2, p=0.01) with longer treatment and continuous use, and was non-significant after discontinuation.
Systemic toxicity is known to be a major concern with long-term use of high-dose glucocorticoids. In our study, the deleterious effect on cognitive function was only observed for inhaled CS. This may be linked to differences in the active substances and/or pharmacodynamic properties related to administration mode; oral administration being generally associated with slower absorption/distribution, higher metabolism due to hepatic first-pass effect, and lower biologically active circulating metabolites. Adrenal insufficiency and Cushing's syndrome have also been reported in patients treated with inhaled CS (Molimard et al., 2008) . In our study, however, the small number of subjects taking CS using either mode did not allow us to examine the effect of administration method. We also did not have any information on patient conformity to prescription; inhaled CS being more likely to be over-dosed.
Only a few small experimental studies in healthy young or adult participants have examined the link between acute or short-term glucocorticoid administration and cognitive impairment. Cognitive assessment has principally focused on changes in declarative memory consistent with deficiencies in hippocampus-dependent activity, although recent studies have also noted impairments in prefrontal cortex processing (Wolkowitz et al., 2009; Lupien et al., 2007; Franz et al., 2011) ; both structures having a relatively high density of gluco-and mineralocorticoid receptors. These associations may be transient and dose-dependent (Newcomer et al., 1999; Kirschbaum et al., 1996; Young et al., 1999; de Quervain et al., 2003; Keenan et al., 1996) . A lower sensitivity of verbal memory skills compared to other cognitive functions has been reported in young adults after acute CS administration and recently in inserm-00782581, version 1 -30 Jan 2013
older adults, in a large study using an extensive cognitive battery; high cortisol levels being specifically associated with poor frontal-executive functions (Franz et al., 2011) . No such studies have been performed in the elderly.
In our study poor performance is only seen on the TMTB and not on the TMTA trial (the A trial not involving the cognitive switching task) and similar results were observed when executive function was assessed using score differences. This thus suggests that executive performance is affected rather than psychomotor speed. Neuropsychological tests requiring intact prefrontal cortical activity such as the TMTB may thus be especially vulnerable to chronic inhaled CS use in elderly women. A "two-factor model of brain aging" which posits that endocrine-related aging, like normal aging, may primarily involve loss of frontal-striatal circuits with associated executive function changes, whereas pathological cognitive aging (e.g. AD) is more strongly associated with hippocampal abnormalities appears to support our observations but remains speculative (Buckner, 2004; Hedden and Gabrieli, 2004; Franz et al., 2011) .
Gender specificity
We did not observe a significant association between CS use and cognitive decline for men. This could be due to pharmacodynamic or metabolism differences. In a meta-analysis, Otte et al.
reported a three-fold stronger effect of age on cortisol response in women than in men (Otte et al., 2005) . A gender difference in biological response to stress both at a functional and structural level may also be possible (Kudielka et al., 2004; Kumsta et al., 2007; Pruessner et al., 2010) .
Overall, specific cognitive functions may be affected by cumulative exposure to chronic stress via glucocorticoids released from the HPA axis, but also from gonadal steroids released from the hypothalamic-pituitary-gonadal axis (notably estrogens and testosterone which have distinct cognitive effects in women and men) (Conrad and Bimonte-Nelson, 2010 
CS use and dementia
We observed no significant association between CS use at baseline and risk of developing dementia over 7-years. To date only one randomized controlled trial has examined the effect of 1-year prednisone treatment on cognitive decline in Alzheimer's patients (Aisen et al., 2000) showing no significant difference between CS and placebo treated patients. CS dose and exposure duration could also be evoked, but the small number of demented subjects taking CS (n=28) have precluded exploration of this possibility.
NSAID use, cognitive decline, and dementia
We did not observe any significant associations between NSAID intake at baseline and cognitive decline and dementia over 7-years. In observational studies, exposure to NSAID were possibly associated with decreased risk for cognitive decline and AD, depending on class and dose, longer duration or younger age at intake, and APO4 vulnerability (Szekely et al., 2004; Szekely et al., 2008; Vlad et al., 2008; de Craen et al., 2005; Gorelick, 2010; Szekely and Zandi, 2010) . Conversely, the three randomized controlled trials performed using rofecoxib, celecoxib and naproxen, suggested an increased risk in AD and no consistent association or worsening of cognitive function with naproxen (in global summary scores and verbal fluency) (Thal et al., 2005; Lyketsos et al., 2007; Martin et al., 2008) .
Inflammatory processes are complex and may have either reparative or detrimental effects on neurons (Wyss-Coray and Mucke, 2002). In our study, neither CS nor NSAID appeared to be beneficial for cognitive dysfunction or dementia, which does not support the hypothesis that inserm-00782581, version 1 -30 Jan 2013
inhibiting inflammation can reduce neurodegenerative processes in the elderly. The different patterns of cognitive change observed in our study between CS and NSAID suggests that deleterious CS effects on executive function may be more likely related to glucocorticoid and HPA axis functioning rather than an anti-inflammatory effect.
Limitations and strengths
A limitation of our study was the use of some self-reported covariates with eventual subsequent recall bias. Bias could also have been introduced through the exclusion of participants, those lost to follow-up being more likely to have dementia, to be older, and thus with worse physical and mental health, and using CS more frequently. This may limit the generalizability of our results, and associations may have thus been underestimated. We did not consider treatment compliance, which may have caused classification bias. Since we did not have data on precise duration of medication use, we could not definitively address the question of whether prolonged use could precipitate non-reversible dementia. Finally, since multiple analyses have been performed we cannot exclude that some observed associations were due to a chance finding.
The strengths of this study relate principally to its prospective, community-based design, large size and extensive information obtained on clinical status. CS and NSAID use was verified by examining prescriptions and medications, thus minimizing exposure misclassification and with the advantage, compared to reimbursement data, of including self-medication (Noize et al., 2009 ). Finally, we have taken into account a wide range of competing causes of cognitive dysfunction in the elderly, by controlling for socio-demographic, genetic, health and lifestyle covariates, thus limiting any potential confounding including prescription bias.
In conclusion, findings from this study suggest that inhaled CS use is associated with poorer executive performance in elderly women; the principal clinical and functional implication inserm-00782581, version 1 -30 Jan 2013
being that medical practitioners should take chronic CS use into account before making a differential diagnosis of early neurodegenerative disorder. 
Appendix A. Supplementary data
Two eTables listing the frequency of use of CS and NSAID among study participants.
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Csernansky, J.G., Dong, H., Fagan, A.M., Wang, L., Xiong, C., Holtzman, D.M., Morris, J.C., a The presence of depressive symptoms was assessed using the Center for Epidemiological StudiesDepression Scale (CES-D) (Radloff, 1977) with a cut-off of >16. b History of stroke, myocardial infarction, angina pectoris, or arteritis and cardio-vascular surgery c Diabetes defined as glucose ≥7 mmol/l or treated. d Chronic bronchitis (with daily sputum or mucus production or cough for at least 3 consecutive months a year). e Asthma attacks and other chronic respiratory disorders including wheezing, tachypnea (over the last 12 months). f Systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 95 mm Hg or intake of antihypertensive drugs. g Total cholesterol level ≥6.2 mmol/l or treated by lipid lowering agents. h one unit = 100 mg caffeine i The % of subjects with lowest cognitive performances at baseline are reported (lowest quintile except for TMT highest quintile). The numbers of subjects completing the TMT tests were for women, 3573 non CS users and 163 users and for men, 2242 non CS users and 107 users (see Methods for detail). CS = Corticosteroid; BMI = body mass index; MMSE = Mini Mental State Examination; NSAID = Nonsteroidal anti-inflammatory drug; TMT = Trail Making Test inserm-00782581, version 1 -30 Jan 2013 3.7 0.3 *43 subjects were using more than one NSAID medication.
